Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis

BACKGROUND/OBJECTIVES: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild‐to‐moderate atopic dermatitis (AD). This pooled post hoc analysis of two phase 3 trials (NCT02118766, NCT02118792) assessed improvement and time to improvement in Investigator&#...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pediatr Dermatol
Autors principals: Eichenfield, Lawrence F., Yosipovitch, Gil, Stein Gold, Linda F., Kalabis, Mizuho, Zang, Chuanbo, Vlahos, Bonnie, Sanders, Paul, Myers, Daniela E., Bushmakin, Andrew G., Cappelleri, Joseph C., Olivadoti, Melissa, Paller, Amy S.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756882/
https://ncbi.nlm.nih.gov/pubmed/32981097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pde.14328
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars